

EXTRAORDINARY REPORT

Egis Pharmaceuticals PLC (Egis) announces that Egis and its business partner Actavis, Inc. (Partner), formerly known as Watson Pharmaceuticals, Inc., have reached a settlement agreement with AstraZeneca resolving the outstanding patent litigation related to the generic version of Crestor® tablets (rosuvastatin calcium), as well as rosuvastatin zinc alternate salt product developed by Egis. Under the terms of the settlement agreement, the Partner can launch its rosuvastatin calcium product, the generic version of Crestor® 67 days prior to July 8, 2016, the expiration of pediatric exclusivity, or earlier under certain circumstances.

As part of the agreement, the Partner is permitted, beginning May 2, 2016 or earlier under certain circumstances, to launch the rosuvastatin zinc alternate salt product, developed by Egis which previously received tentative approval from the FDA in August 2011. However, at this time, the Partner has made no decision regarding a potential launch. Based on the contractual arrangements made between Egis and its Partner, Egis will also benefit from the sales of the Partner's generic rosuvastatin calcium which previously was granted a tentative approval by the FDA in June 2011.

About Egis

The Budapest-based Hungarian Egis Pharmaceuticals Public Limited Company is one of the leading regional generic pharmaceutical companies the operational focus of which is Central Europe, Russia and the CIS countries. Its scope of activity includes development, manufacture and marketing of finished pharmaceuticals and active pharmaceutical ingredients suitable for treatment of cardiovascular diseases, disorders of the central nervous system, the respiratory and digestive systems.

Crestor® is the trademark of the AstraZeneca group of companies.

Budapest, March 25, 2013

Egis Pharmaceuticals PLC